MDxHealth (MDXH.BR) Stock Price
MDxHealth Price
Revenue has compounded at 19.5% per year over the past 19 years to 94.73 M USD. MDxHealth's net margin stands at -31.1%, up from -130.4% several years earlier. Analysts set a median price target of 7.39 USD, implying 124.7% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.
MDxHealth stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of MDxHealth over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how MDxHealth stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing MDxHealth's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | MDxHealth Price |
|---|
MDxHealth Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
MDxHealth Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.00 | 6.00 | 10.00 | 15.00 | 26.00 | 35.00 | 24.00 | 10.00 | 16.00 | 19.00 | 32.00 | 61.00 | 79.00 | 94.00 | 113.00 | 129.00 |
| 33.33 | 50.00 | 66.67 | 50.00 | 73.33 | 34.62 | -31.43 | -58.33 | 60.00 | 18.75 | 68.42 | 90.63 | 29.51 | 18.99 | 20.21 | 14.16 |
| 75.00 | 16.67 | 40.00 | 60.00 | 65.38 | 74.29 | 58.33 | 560.00 | 43.75 | 47.37 | 50.00 | 62.30 | 60.76 | 59.57 | 59.57 | 59.57 |
| 3.00 | 1.00 | 4.00 | 9.00 | 17.00 | 26.00 | 14.00 | 56.00 | 7.00 | 9.00 | 16.00 | 38.00 | 48.00 | 56.00 | 67.32 | 76.85 |
| -10.00 | -14.00 | -13.00 | -12.00 | -11.00 | -10.00 | -28.00 | -37.00 | -23.00 | -23.00 | -36.00 | -28.00 | -26.00 | -20.00 | 3.00 | 18.00 |
| -250.00 | -233.33 | -130.00 | -80.00 | -42.31 | -28.57 | -116.67 | -370.00 | -143.75 | -121.05 | -112.50 | -45.90 | -32.91 | -21.28 | 2.65 | 13.95 |
| -10.00 | -14.00 | -13.00 | -12.00 | -11.00 | -10.00 | -28.00 | -37.00 | -25.00 | -25.00 | -38.00 | -37.00 | -33.00 | -29.00 | 2.00 | 16.00 |
| 42.86 | 40.00 | -7.14 | -7.69 | -8.33 | -9.09 | 180.00 | 32.14 | -32.43 | – | 52.00 | -2.63 | -10.81 | -12.12 | -106.90 | 700.00 |
| 30.04 | 34.76 | 41.28 | 46.08 | 49.91 | 57.61 | 62.58 | 70.53 | 90.69 | 155.97 | 62.58 | 251.13 | 251.13 | 251.13 | 251.13 | 251.13 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales MDxHealth generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue MDxHealth retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare MDxHealth's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares MDxHealth has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against MDxHealth's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
MDxHealth stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
MDxHealth Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
MDxHealth business model & stock analysis
MDxHealth SWOT Analysis
Strengths
MDxHealth SA benefits from a strong market position in the field of molecular diagnostics. The company has developed innovative diagnostic tests that provide valuable information for doctors and patients in the diagnosis and treatment of various types of cancer. This expertise has helped MDxHealth establish a solid reputation and gain the trust of healthcare professionals.
Furthermore, MDxHealth has a diverse portfolio of diagnostic products, catering to different cancer types. This diversity minimizes the company's dependency on a single product, allowing for a more stable revenue stream. Additionally, MDxHealth's tests are non-invasive and often provide results faster than traditional tests, offering a competitive advantage in terms of convenience for patients and healthcare providers.
Weaknesses
One major weakness for MDxHealth is its dependence on regulatory approvals for its products. The diagnostic industry is heavily regulated, and delays in obtaining necessary approvals can hamper the company's ability to successfully commercialize its tests. This dependency exposes MDxHealth to potential delays and uncertainties, impacting its market presence and competitive standing.
Additionally, MDxHealth faces significant competition from other companies in the molecular diagnostics industry. Rival firms may develop similar tests, reducing MDxHealth's market share and potentially eroding its pricing power. The company needs to continuously innovate and enhance its testing capabilities to stay ahead of competitors.
Opportunities
MDxHealth has the opportunity to expand its market presence by entering new geographic regions. Currently, the company mainly operates in Europe and the United States, but it could explore partnerships and licensing agreements to enter untapped markets in Asia and other regions. This expansion would provide access to a larger patient population and increase potential revenues.
Moreover, with the growing focus on personalized medicine, MDxHealth can capitalize on advancements in genomics and other technologies to develop new diagnostic tests tailored to individual patients. By leveraging these opportunities, MDxHealth can stay at the forefront of molecular diagnostics and provide more targeted and effective solutions for cancer detection and treatment.
Threats
MDxHealth faces the threat of reimbursement challenges. Given the evolving healthcare landscape and cost containment measures, there is a risk that payers, such as insurance companies and government healthcare systems, may limit coverage or reimbursement rates for diagnostic tests. This could negatively impact MDxHealth's revenue and profitability.
Additionally, the molecular diagnostics industry is subject to rapid technological advancements and changing customer needs. MDxHealth needs to continuously invest in research and development to stay ahead of these changes. Failure to adapt to emerging trends and technologies could result in the company's products becoming obsolete and losing market share to more innovative competitors.
MDxHealth Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
MDxHealth historical P/E ratio, EBIT multiple, and P/S ratio
MDxHealth annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
MDxHealth shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
MDxHealth stock splits
Current MDxHealth forecasts and price targets in August 2026
Analyst Price Targets 2026MDxHealth Analyst Rating Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| 5/31/2023 | Maintained | Outperform | |
| 5/15/2023 | Maintained | Buy | |
| 4/19/2023 | Maintained | Buy | |
| 3/24/2023 | Maintained | Outperform | |
| 3/8/2023 | Maintained | Buy | |
| 3/5/2023 | Maintained | Overweight | |
| 11/8/2022 | Maintained | Buy | |
| 10/30/2022 | Maintained | Buy | |
| 8/25/2022 | Maintained | Buy | |
| 11/29/2021 | Maintained | Overweight |
MDxHealth Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 8/26/2020 | -0.16USD | 11.82 MUSD | 2020 Q2 |
| 8/30/2018 | -0.19USD | 18.02 MUSD | 2018 Q2 |
| 8/31/2017 | -0.13USD | 23.21 MUSD | 2017 Q2 |
| 3/11/2010 | -0.92USD | 1.16 MUSD | 2009 Q4 |
| 8/27/2009 | -0.62USD | 2.36 MUSD | 2009 Q2 |
| 3/12/2009 | -0.73USD | 1.97 MUSD | 2008 Q4 |
| 8/28/2008 | -0.67USD | 3.27 MUSD | 2008 Q2 |
| 3/13/2008 | -0.69USD | 1.39 MUSD | 2007 Q4 |
MDxHealth shareholder structure
| % | Name |
|---|---|
100.27813% | |
85.35579% | |
45.96081% | |
26.26332% | |
4.99036% | |
0.07139% |
MDxHealth Beneficial Ownership Filings (SEC 13D/G)
MDxHealth Supply Chain
MDxHealth Supply Chain
Correlation: how closely stock prices move together
| # | Name | 1M | 3M | 6M | 1Y | 2Y | Trend |
|---|---|---|---|---|---|---|---|
| 1 | 0.13 | -0.36 | 0.46 | 0.92 | 0.56 | ||
| 2 | 0.55 | -0.38 | 0.65 | 0.43 | 0.50 | ||
| 3 | 0.21 | -0.34 | 0.75 | 0.85 | 0.49 |
| # | Name | 1M | 3M | 6M | 1Y | 2Y | Trend |
|---|---|---|---|---|---|---|---|
| 1 | Epigenomics | -0.14 | -0.23 | 0.43 | 0.96 | -0.44 | |
| 2 | 0.29 | 0 | 0.74 | 0.42 | 0.26 | ||
| 3 | -0.06 | -0.24 | -0.11 | 0.58 | 0.27 |
Frequently asked questions about MDxHealth
The business model of MDxHealth SA revolves around providing innovative molecular diagnostic solutions to improve the diagnosis and treatment of cancer. The company primarily focuses on developing and commercializing diagnostic tests that aid in the early detection, prognosis, and monitoring of various types of cancers, including prostate, bladder, and lung cancer. MDxHealth offers its diagnostic tests through a global network of clinical laboratories and medical institutions. By offering accurate and actionable diagnostic information, MDxHealth aims to support healthcare professionals in making informed treatment decisions and ultimately improving patient outcomes. MDxHealth's business model underscores its commitment to advancing personalized medicine and precision oncology.
MDxHealth stock
MDxHealth Peer Group
MDxHealth Ticker
MDxHealth FIGI
All fundamentals and in-depth analysis of MDxHealth
Our stock analysis for MDxHealth stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MDxHealth. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.